Table 2 | Effects of potassium-adaptation on plasma..

Treatment	Na⁺	K⁺	HCO3^-	Cl^-
C (2ml/kg)	139.0±2.08	4.8±0.15	26.2±1.16	104.3±1.50
A	142.8±2.15	5.0±0.24	21.2±1.86^{b, ad}	102.4±1.17
G	142.0±1.14	4.5±0.18	26.8±0.74	105.4±1.32
AG	143.8±1.56	4.6±0.22	27.2±0.86	106.0±1.79
K	146.0±1.09 ^b	5.3±0.36	24.4±0.40	105.2±1.49
KAG	144.6±1.78	4.6±0.16	25.0±0.55	105.8±1.74
D	140.8±1.08	4.6±0.12	24.2±0.54^ac	103.4±1.78
DG	145.6±2.11	5.0±0.28	25.4±1.63^ac	103.4±1.78
DGA	142.0±1.38	4.8±0.07	24.2±0.50	105.6±1.57
KDGA	145.4±1.87	4.6±0.22	24.8±0.86	107.0±1.00

Values are mean + SEM.
(n=5 per group).
^bp<0.05 significantly different from the control. ^abp<0.05 significantly different from the diabetic group treated with gilbenclamide and amlodipine , ^acp<0.05 significantly
different from the potassium adapted group and ^cp<0.05 significantly different from the normal group treated with amlodipine and glibenclamide.
C: Control (normal saline group)
A: Normal group treated with amlodipine
G : Normal group treated with glibenclamide
AG: Normal group treated with both amlodipine and glibenclamide
K: Potassium adapted group
KAG: Potassium adapted treated with both glibenclamide and amlodipine
D: Diabetic group
DG: Diabetic group treated with glibenclamide
DGA: Non-adapted diabetic group treated with both glibenclamide and amlodipine
KDAG: potassium adapted diabetic group treated with both amlodipine and glibenclamide

Table 2: Effects of potassium-adaptation on plasma electrolytes of normal and streptozotocin- induced diabetic rats treated with glibenclamide (5 mg/kg) and amlodipine (5 mg/kg).

Goto home»